Danaher Corporation
DHR Healthcare Diagnostics & Research
Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024. In the quarter to June 2026, revenue grew 5.54%, EPS grew 59.7%, free cash flow grew 15.6% and total debt rose 49.2%, each against the same quarter a year earlier. Member of the S&P 500.
Follow DHR
Danaher Corporation (DHR) Net income
Danaher Corporation's net income for fiscal 2025 was $3.6B, down 7.31% from $3.9B in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.0B. Over the past ten years it has ranged from $2.5B (fiscal 2017) to $7.2B (fiscal 2022); the current reading is higher than 55% of that period. Net income has fallen for 3 consecutive fiscal years. Danaher Corporation ranks 2nd of 52 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $3.6B | (7.31%) |
| FY2024 | $3.9B | (18.16%) |
| FY2023 | $4.8B | (33.92%) |
| FY2022 | $7.2B | 12.06% |
| FY2021 | $6.4B | 76.44% |
| FY2020 | $3.6B | 21.21% |
| FY2019 | $3.0B | 13.47% |
| FY2018 | $2.7B | 6.38% |
| FY2017 | $2.5B | (2.41%) |
| FY2016 | $2.6B | (23.94%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $870.0M | (15.45%) |
| Mar 2026 | $1.0B | (14.04%) |
| Dec 2025 | $1.2B | 31.83% |
| Sep 2025 | $908.0M | 63.60% |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TMO Thermo Fisher Scientific Inc. compare | $7.0B |
| DHR Danaher Corporation | $4.0B |
| A Agilent Technologies, Inc. compare | $1.4B |
| IQV IQVIA Holdings Inc. compare | $1.4B |
| IDXX IDEXX Laboratories, Inc. compare | $1.1B |
| MTD Mettler-Toledo International, Inc. compare | $905.6M |
| ILMN Illumina, Inc. compare | $824.0M |
| WAT Waters Corporation compare | $166.6M |
| NTRA Natera, Inc. compare | −$192.3M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on DHR
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement